Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: Current situation and future challenges

Haematologica

Volumn 99, Issue 3, 2014, Pages 437-447

  Noens, Lucien ^a   Hensen, Marja ^b   Kucmin Bemelmans, Izabela ^b   Lofgren, Christina ^c   Gilloteau, Isabelle ^c   Vrijens, Bernard ^d,e  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b PHARMERIT INTERNATIONAL   (Netherlands)

^c BRISTOL MYERS SQUIBB   (United States)

^d MWV Healthcare   (Switzerland)

^e UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; PROTEIN KINASE INHIBITOR;

BLOOD SAMPLING; CHARLSON COMORBIDITY INDEX; CHRONIC MYELOID LEUKEMIA; DISEASE DURATION; DISEASE SEVERITY; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE COST; HUMAN; MULTIPLE MYELOMA; PATIENT COMPLIANCE; PHYSICIAN; PREVALENCE; QUALITY CONTROL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEDICATION COMPLIANCE; META ANALYSIS;

ANTINEOPLASTIC AGENTS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEDICATION ADHERENCE; PATIENT COMPLIANCE; PROTEIN KINASE INHIBITORS;

EID: 84895746438     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.082511     Document Type: Review

References (83)

1. Baccarani M, Dreyling M, ESMO Guidelines Working Group. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl. 5):v165-7.
2. NCCN. org [Internet]. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology (NCCN Guidelines™). Chronic myelogenous leukemia. Version 2.2011 [accessed 2011]. Available from: http://www.nccn.org/professionals/physician_ gls/pdf/cml.pdf.
3. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340(17):1330-40.
4. Alvarez RH, Kantarjian H, Cortes JE. The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin Hematol. 2007;44(1 suppl. 1):S4-14.
5. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041-51.
6. Pharma. US. Novartis. com [Internet]. Novartis Pharmaceuticals Corporation: GLEEVEC (imatinib mesylate) tablets for oral use prescribing information. East Hanover, NJ, USA, 2013 [accessed 2013]. Available from: www.pharma.us.novartis.com/product/pi/ pdf/gleevec_tabs.pdf.
7. Packageinserts. BMS. com [Internet]. Bristol-Myers Squibb Company: Sprycel® (dasatinib) capsules prescribing information. Princeton, NJ, USA, 2006 [accessed 2011]. Available from: http://packageinserts.bms. com/pi/pi_sprycel.pdf.
8. Pharma. US. Novartis. com [Internet]. Novartis Pharmaceuticals Corporation: Tasigna® (nilotinib) capsules prescribing information. East Hanover, NJ, USA, 2012 [accessed 2013]. Available from: http://www.pharma.us.novartis.com/product/ pi/pdf/tasigna.pdf.
9. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260-70.
10. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362 (24):2251-9.
11. Hochhaus A, Shah NP, Cortes JE, Baccarani M, Bradley-Garelik MB, Dejardin D, et al. Dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up. J Clin Oncol. 2012;30(suppl.):Abstract 6504.
12. Kantarjian H, Flinn IW, Goldberg S, Bunworasate U, Zanichelli MA, Nakamae H, et al. Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u). J Clin Oncol. 2012;30(suppl.)Abstract 6509.
13. Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Ann Rev Pharmacol Toxicol. 2012;52:275-301.
14. Noens L, van Lierde MA, De Bock R, Verhoef G, Zachée P, Berneman Z, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113(22): 5401-11.
15. Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Buaet M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381-8.
16. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. BMJ. 2009;339:332-6.
17. Cochrane-Handbook. org [Internet]. Cochrane Collaboration: Cochrane handbook for systematic reviews of interventions. 2011 [accessed 2011]. Available from: http://www.cochrane-handbook.org/.
18. Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, et al. Imatinib and pegylated human recombinant interferon-alpha2b in early chronicphase chronic myeloid leukemia. Blood. 2004;104(13):4245-51.
19. Breccia M, Efficace F, Alimena G. Imatinib treatment in chronic myelogenous leukemia: What have we learned so far? Cancer Lett. 2011;300(2):115-121.
20. Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007; 25(6):481-96.
21. Eliasson L, Clifford S, Barber N, Marin D. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res. 2011;35(5):626-30.
22. Ganesan P, Sagar TG, Dubashi B, Rajendranath R, Kannan K, Cyriac S, et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol. 2011;86(6):471-4.
23. Halpern R, Barghout V, Zarotsky V, Williams D. Costs and utilization associated with imatinib adherence in patients with chronic myeloid leukemia or gastrointestinal stromal tumors. J Clin Outcomes Manag. 2009;16(5):215-23.
24. Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011;117(14):3733-6.
25. Jönsson S, Olsson B, Söderberg J, Wadenvik H. Good adherence to imatinib therapy among patients with chronic myeloid leukemia-a single-center observational study. Ann Hematol. 2012;91(5):679-85.
26. Kiguchi T, Tauchi T, Ito Y, Miyazawa K, Kimura Y, Ohyashiki K. Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase. Leuk Res. 2009;33(3):506-8.
27. Kong DC, Dooley MJ, Stewart K, Larizza MA. Factors influencing adherence to molecular therapies in haematology-oncology outpatients. J Pharm Prac Res. 2006; 36(2):115-8.
28. Moon JH, Sohn SK, Kim SN, Park SY, Yoon SS, Kim IH, et al. Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients. Med Oncol. 2012;29(2):1179-85.
29. Muramatsu H, Takahashi Y, Sakaguchi H, Shimada A, Nishio N, Hama A, et al. Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era. Int J Hematol. 2011;93(2):186-91.
30. Prejzner W. Compliance during therapy of patients with chronic myeloid leukemia. Hematologica. 2010;1(3):239-43.
31. Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin. 2010;26(12):2861-9.
32. Wu EQ, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A, et al. Healthcare resource utilization and costs associated with nonadherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin. 2010;26(1):61-9.
33. Yood MU, Oliveria SA, Cziraky M, Hirji I, Hamdan M, Davis C. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr Med Res Opin. 2012;28(2):213-9.
34. Yood MU, Oliveria SA, Hirji I, Cziraky M, Davis C. Adherence to treatment in patients with chronic myelogenous leukemia (CML) during a 10-year time period: a medical record review. Blood. 2010;116(21):Abstract 4492.
35. Yoshida C, Komeno T, Hori M, Kimura T, Fujii M, Okoshi Y, et al. Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia. Int J Hematol. 2011;93(5):618-23.
36. Almeida M, Pagnano K, Souza H, Miranda E, De Souza C. High adherence to Tyrosine Kinase Inhibitors seems to be related to best cytogenetic response in the hasford lower risk group in Chronic Myeloid Leukemia. Blood. 2010;116(21):Abstract 4477.
37. Almeida MH, Pagnano KB, Miranda EC, Souza CA. Higher adherence related to complete molecular response (CMR) in chronic myeloid leukemia patients using imatinib mesilate. Haematologica. 2011;96(suppl. 2):Abstract 678.
38. Almeida MH, Barbosa Pagnano KB, Sanges Souza HA, Souza CA. Adherence to tyrosine kinase inhibitors (TKI) in chronic myeloid leukemia (CML) seems to be related to duration of treatment and type of TKI. Haematologica. 2010;95(suppl. 2): Abstract 820.
39. Daouphars M, Ouvry M, Lenain P, Rouvet J, Varin R. Adherence assessment in Chronic Myeloid Leukaemia patients treated by tyrosine kinase inhibitors. Int J Clin Pharm. 2011;33:414-15.
40. Doti CA, Stemmelin GR, Moiraghi EB, Flores MG, Garcia J, Murro H, et al. Adherence to imatinib mesylate treatment: two years follow up. Blood. 2008;112(11): Abstract 4267.
41. Fogliatto L, Capra M, Schaan M, Fassina K, Fernandes MS, Schilling MA, et al. Impact of comorbidity in event-free survival, toxicity and adherence to treatment in chronic myeloid leukemia patients treated with imatinib. Blood. 2010;116(21):Abstract 2296.
42. Funke VAM, Moellmann-Coelho A, Asano E, Nita ME, Donato BM, Rahal E. Impact of non-adherence to Imatinib on progressionfree survival a 1st treatment for Chronic Myeloid Leukemia in Brazil: two years follow up. Value Health. 2011;14(3):A168-9.
43. Gupta S, Goren A, Victor TW, Chapnick J, Hawthorne S, Hirji I, et al. Associations between treatment restrictions, patientreported treatment burden and adherence to tyrosine-kinase inhibitor therapy among Chronic Myeloid Leukemia patients in the United States and Europe. Blood. 2011;118 (21):Abstract 2077.
44. Guilhot F, Coombs J, Zernovak O, Szczudlo T, Rosti G. A global retrospective and physician-based analysis of adherence to tyrosine kinase inhibitor (TKI) therapies for chronic myeloid leukemia (CML). Blood. 2010;116(21):Abstract 1514.
45. Hirji I, Joo S, Davis C. Treatment adherence and resource use costs in chronic myeloid leukemia [poster]. American Society of Health-System Pharmacists Congress. 2011:Abstract 40-M.
46. Johnson CN, Cowan L, Gorospe GL, Ailawadhi S. Disease knowledge in chronic myeloid leukemia (CML) patients as a predictor of compliance to treatment. Blood. 2010;116(21):Abstract 4481.
47. Koren-Michowitz M, Volchek Y, Ben-Yehuda D, Naparstek E, Gavish I, Levi E, et al. Imatinib trough plasma levels in Philadelphia positive chronic myeloid leukemia (CML) patients: results of a multicenter study CSTI571AIL11TGLIVEC. Hematologica. 2010;95(suppl. 2):Abstract 0809.
48. Kutsev S, Oxenjuk O, Kravchenko E, Shatokhin Y, Bogdanova Y, Burnasheva E, et al. The role of imatinib plasma level test in evaluation of the nonadherence to therapy in chronic myelogenous leukemia patients. Hematologica. 2010;95(suppl. 2):Abstract 0817.
49. Lee S, Johnson C, Sandoval Y, Gorospe G, Yang AS, Ailawadhi S. Imatinib meslylate plasma levels predict compliance in patients with chronic myelogenous leukemia. Blood. 2009;114(22):Abstract 4274.
50. Palandri F, Castagnetti F, Iacobucci I, Amabile M, Gugliotta G, Poerio A, et al. The combination of interferon-alpha with imatinib in early chronic phase chronic myeloid leukemia patients induces a significant improvement of the molecular responses in the first two years of treatment: results from three studies from the GIMEMA CML Working Party. Blood. 2009;114(22):Abstract 2192.
51. Rosti G, Castagnetti F, Poerio A, Breccia M, Levato L, Capucci A, et al. High and early rates of cytogenetic and molecular response with nilotinib 800 mg daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: results of a phase 2 trial of the GIMEMA CML Working Party. Blood. 2008;112(11): Abstract 181.
52. St Charles M, Bollu VK, Hornyak E, Coombs J, Blanchette CM, DeAngelo DJ. Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia. Blood. 2009;114(22):Abstract 2209.
53. Wu EQ, Guerin A, Bollu VK, Guo A, Cloutier M, Ponce de Leon Barido D, et al. Impact of pleural effusion (PE) on treatment adherence, discontinuation, switching, and dose modification in patients with chronic myelogenous leukemia (CML). J Clin Oncol. 2011;29(suppl.):Abstract 6616.
54. Wu S, Chee D, Ugalde A, Butow P, Seymour J, Schofield P. What doctors don't know about adherence: a qualitative study of adherence to imatinib amongst patients with chronic myeloid leukaemia. Psychooncology. 2011;20(suppl. 2):Abstract P1-127.
55. Gossec L, Tubach F, Dougados M, Ravaud P. Reporting of adherence to medication in recent randomized controlled trials of 6 chronic diseases: a systematic literature review. Am J Med Sci. 2007;334(4):248-54.
56. Gordis L. Conceptual and methodological problems in measuring compliance. In: Haynes RB, Taylor DW, Sackett DL, eds. Compliance in Health Care. Baltimore, MD: Johns Hopkins University Press. 1979;23-5.
57. Haynes RB, Taylor DW, Sackett DL, eds. Compliance in Health Care. Baltimore, MD: Johns Hopkins University Press. 1979;49-62.
58. Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. The rational clinical examination. Is the patient taking the treatment as prescribed? JAMA. 1993;269(21):2779-81.
59. Eze UIH, Ojieabu WA, Femi-Oyewo MN, Martins OO. Evaluation of adherence in elderly diabetic hypertensive patients. J Hosp Clin Pharm. 2011;1(4).
60. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691-705.
61. Koren-Michowitz M, Volchek Y, Naparstek E, Gavish I, Levi I, Rowe JM, et al. Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC. Hematol Oncol. 2012;30(4):200-5.
62. Rezende VM, Rivellis AJ, Gomes MM, Dörr FA, Novaes MM, Nardinelli L, et al. Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance. Rev Bras Hematol Hemoter. 2013;35(2):103-8.
63. Daouphars M, Ouvry M, Lenain P, Rouvet J, Jardin F, Bubenheim M, et al. Preliminary validation of self-assessment tool to measure imatinib adherence in patients with chronic myeloid leukemia. Pharmacotherapy. 2013;33(2):152-6.
64. Vrijens B, Tousset E, Rode R, Bertz R, Mayer S, Urquhart J. Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models. J Clin Pharmacol. 2005;45(4):461-7.
65. Demonceau J, Ruppar T, Kristanto P, Hughes DA, Fargher E, Kardas P, et al. Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis. Drugs. 2013;73(6):545-62.
66. Guérin A, Chen L, Wu EQ, de Leon DP, Griffin JD. A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. Curr Med Res Opin. 2012;28(7):1155-62.
67. Santoleri F, Sorice P, Lasala R, Rizzo RC, Costantini A. Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice. PLoS One. 2013;8(2): e56813.
68. Stone VE, Hogan JW, Schuman P, Rompalo AM, Howard AA, Korkontzelou C, et al. Antiretroviral regimen complexity, selfreported adherence, and HIV patients' understanding of their regimens: survey of women in the her study. J Acquir Immune Defic Syndr. 2001;28(2):124-31.
69. Sax PE, Meyers JL, Mugavero M, Davis KL. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One. 2012;7(2): e31591.
70. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989;261 (22):3273-7.
71. Iskedjian M, Einarson TR, MacKeigan LD, Shear N, Addis A, Mittmann N, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther. 2002;24(2):302-16.
72. Comté L, Vrijens B, Tousset E, Gérard P, Urquhart J. Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics. J Pharmacokinet Pharmacodyn. 2007;34(4):549-58.
73. Muluneh B, Alexander M, Deal AM, Deal M, Markey J, Neal J, et al. Prospective evaluation of perceived barriers to medication adherence by patients on oral antineoplastics. J Clin Oncol. 2012;30(suppl.):Abstract 6042.
74. Efficace F, Baccarani M, Rosti G, Cottone F, Castagnetti F, Breccia M, et al. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer. 2012; 107(6):904-9.
75. Abraham I, Lee C, MacDonald K, van Lierde M-A, Beaver M, Geest SD, et al. No margin for nonadherence: novel application of Kaplan-Meier methods to model the efficacy of adherence to imatinib treatment by patients with chronic myeloid leukemia (the ADAGIO Study). European Society for Patient Adherence, COMpliance, and Persistence Ghent, Belgium, October 25-27, 2012:Abstract 4.
76. Viswanathan M, Golin CE, Jones CD, Ashok M, Blalock S, Wines RCM, et al. Closing the quality gap: revisiting the state of the science (Vol. 4: Medication adherence interventions: comparative effectiveness). Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Sep. (Evidence Reports/Technology Assessments, No. 208.4.) Available from: http://www.ncbi.nlm.nih.gov/books/NBK1 14350/
77. Finkler SA. The distinction between cost and charges. Ann Intern Med. 1982; 96(1):102-9.
78. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-30.
79. Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm. 2011;17(1):25-39.
80. Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-35.
81. Gater A, Heron L, Abetz-Webb L, Coombs J, Simmons J, Guilhot F, et al. Adherence to oral kinase inhibitor therapies in chronic myeloid leukemia. Leuk Res. 2012;36(7): 817-25.
82. Wu S, Chee D, Ugalde A, Butow P, Seymour J, Schofield P. Patient's and health professionals' perspectives of adherence and imatinib therapy in treatment of chronic myeloid leukaemia. Asia Pac J Clin Oncol. 2011;7(suppl. 4):Abstract 305.
83. Winkeljohn DL. Oral chemotherapy medications: the need for a nurse's touch. Clin J Oncol Nurs. 2007;11(6):793-6.